Anetumab ravtansine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Anetumab ravtansine
DrugBank Accession Number
DB14809
Background

Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).

Type
Biotech
Groups
Investigational
Synonyms
  • Anetumab ravtansine
  • BAY 94-9343

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Anetumab ravtansine.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Anetumab ravtansine.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Anetumab ravtansine.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anetumab ravtansine.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Anetumab ravtansine.
AmivantamabThe risk or severity of adverse effects can be increased when Anetumab ravtansine is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Anetumab ravtansine.
AnsuvimabThe risk or severity of adverse effects can be increased when Anetumab ravtansine is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Anetumab ravtansine.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Anetumab ravtansine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
M170940PMI
CAS number
1375258-01-7

References

General References
Not Available
Wikipedia
ImmunoGen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentMalignancies1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMesotheliomas1
2RecruitingTreatmentFallopian Tube Endometrioid Adenocarcinoma / High Grade Fallopian Tube Serous Adenocarcinoma / High Grade Ovarian Serous Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Platinum-Resistant Fallopian Tube Carcinoma / Platinum-Resistant Ovarian Carcinoma / Platinum-Resistant Primary Peritoneal Carcinoma / Primary Peritoneal High Grade Serous Adenocarcinoma1
2TerminatedTreatmentNeoplasms, Lung1
1CompletedTreatmentNeoplasms2
1CompletedTreatmentNeoplasms, Ovarian1
1CompletedTreatmentOncology, Medical2
1TerminatedTreatmentMesothelin Positive / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IV Non-Small Cell Lung Cancer AJCC v71
1, 2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 14:28 / Updated on February 21, 2021 18:54